• Enkam presents new results at the Society for Neur
• Commercial Partnership with STEMCELL Technologies
• ENKAM Pharmaceuticals Engages The Sage Group as Ad
• Lead Drug FGL Found To Prevent Impaired Cognition
• R&D Update, Publication & Conference Presentation
• CHDI selects ENKAM’s compounds for preclinical tes
• Presentation at BIO-Europe
• Attendance at Conferences
• Participation at Conference
• The ENKAM approach shows potential in treatment of
• Discovery of Novel Compound Classes
• Positive Preclinical Data - Traumatic Brain Injury
• Appointment of Executive Chairman
• New Promising Treatment of Alzheimer’s Disease
• EU 6FP Grants EUR9.7 million to European Research
• Glossary

The ENKAM approach shows potential in treatment of diabetes

_________________________________________________________________________________

Copenhagen, Denmark, September 11 2006 - ENKAM Pharmaceuticals A/S, the Copenhagen-based biotechnology company focused on cancer and neurodegenerative diseases, is pleased to note that the neural cell adhesion molecule (NCAM) derived peptide, C3d, has the potential to protect insulin producing beta cells against autoimmune induced toxicity which may pay a role in treatment of type I diabetes, as concluded by Petersen et al, in a recent publication in Diabetologia^[[1]. In the paper Petersen et al. presented new proof of concept data showing that modulation of NCAM signalling can modify pro-apoptotic signalling in insulin-producing beta cells.

Although still preliminary this data is exciting as it confirms findings for other applications across ENKAM’s discovery projects. Furthermore, it confirms that NCAM is an important drug discovery platform.

Commenting on this announcement, Morten Albrechtsen MD, Chief Executive and a founder of ENKAM Pharmaceuticals, said:“This is an exciting time for ENKAM as our development projects in the key areas of cancer and neurosciences are all advancing through important milestones. ENKAM plans to have 4 compounds in phase II in 2008. We will explore opportunities to partner this novel approach for developing new treatments for diabetes.”

Vladimir Berezin, Enkam’s Chief Scientific Officer, added:“This is an early but encouraging piece of data that establishes the NCAM molecule as a novel potential therapeutic target for Type I diabetes. This published data also address an emerging new concept in the development of drugs for the treatment of metabolic diseases.”

Reference

[1]Petersen LG, Størling J, Heding P, Li S, Berezin V, Saldeen J, Billestrup N, Bock E, Mandrup-Poulsen T: IL-1β-induced pro-apoptotic signalling is facilitated by NCAM/FGF receptor signalling and inhibited by the C3d ligand in the INS-1E rat beta cell line. Diabetologia. 2006 Aug;49(8):1864-75